Tenet Healthcare THC Impairment and restructuring charges, and acquisition-related costs
Impairment and restructuring charges, and acquisition-related costs at other companies
Other financials
Where this comes from
Reported directly by Tenet Healthcare in its filing.
Tagged under the XBRL concept thc:RestructuringSettlementImpairmentProvisionsAndAcquisitionCost.
The official record: Tenet Healthcare’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs?
- Tenet Healthcare (THC) reported impairment and restructuring charges, and acquisition-related costs of $24M in Q1 2026.
- How has Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs changed year-over-year?
- Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs increased by 26.3% year-over-year, from $19M to $24M.
- What is the long-term trend for Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs?
- Over 4 years (2021 to 2025), Tenet Healthcare's impairment and restructuring charges, and acquisition-related costs has grown at a 11.2% compound annual growth rate (CAGR), from $85M to $130M.
- What does impairment and restructuring charges, and acquisition-related costs mean?
- One-time costs related to reorganizing the business, writing down asset values, or integrating acquisitions.
- How do you interpret impairment and restructuring charges, and acquisition-related costs?
- High levels indicate significant organizational change or asset write-downs, which may be necessary for long-term health but negatively impact short-term earnings.
- How does impairment and restructuring charges, and acquisition-related costs compare across companies?
- Commonly reported as 'special items' or 'non-recurring charges' by public companies.